梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TEVA 梯瓦制药

休市中 07-17 16:00:00 EDT

32.03

-0.19

-0.59%

盘后32.03

+0.000.00%

19:45 EDT

最高32.69	最低31.96	成交量361.24万
今开32.13	昨收32.22	日振幅2.28%
总市值373.15亿	流通市值346.88亿	总股本11.65亿
成交额1.17亿	换手率0.33%	流通股本10.83亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TEVA","market":"US","secType":"STK","nameCN":"梯瓦制药","latestPrice":32.03,"timestamp":1784318400000,"preClose":32.22,"halted":0,"volume":3612359,"hourTrading":{"tag":"盘后","latestPrice":32.03,"preClose":32.03,"latestTime":"19:45 EDT","volume":325747,"amount":10433696.615,"timestamp":1784331944211,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.005896958410924821,"floatShares":1083000000,"shares":1165000000,"eps":1.339126,"marketStatus":"休市中","change":-0.19,"latestTime":"07-17 16:00:00 EDT","open":32.13,"high":32.69,"low":31.955,"amount":116535329.890466,"amplitude":0.022812,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.339126,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1784534400000},"marketStatusCode":7,"adr":0,"adrRate":1,"exchange":"NYSE","adjPreClose":32.22,"preHourTrading":{"tag":"盘前","latestPrice":32.2,"preClose":32.22,"latestTime":"09:09 EDT","volume":531,"amount":16975.821492,"timestamp":1784293783035,"change":-0.02,"changeRate":-0.000621,"amplitude":0.012415},"postHourTrading":{"tag":"盘后","latestPrice":32.03,"preClose":32.03,"latestTime":"19:45 EDT","volume":325747,"amount":10433696.615,"timestamp":1784331944211,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7434209870839167,"impliedVol":0.4973,"impliedVolPercentile":0.8327},"requestUrl":"/m/hq/s/TEVA","defaultTab":"news","newsList":[{"id":"2651170822","title":"联邦上诉法院重启礼来(LLY)专利诉讼 仿制药上市争议再度发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=2651170822","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651170822?lang=zh_cn&edition=full","pubTime":"2026-07-14 19:09","pubTimestamp":1784027386,"startTime":"0","endTime":"0","summary":"梯瓦制药直至2023年12月才正式推出对应仿制药产品，随后在2024年发起诉讼，主张礼来公司依托新增独家销售权，人为阻碍仿制药如期上市，损害自身合法经营权益。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302534","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","LU1064131342.USD","LLYX","IE0009355771.USD","IHE","LU0203201768.USD","LU0109391861.USD","LU0114720955.EUR","LU1548497426.USD","LU1551013342.USD","BK4516","IE00BJJMRY28.SGD","LU0466842654.USD","LU1868837136.USD","LU2087625088.SGD","FHLC","IE00BK4W5M84.HKD","SG9999014914.USD","LU0079474960.USD","LU2756315318.SGD","IE00B4JS1V06.HKD","LU0354030438.USD","LU0456855351.SGD","LU0234572021.USD","LU2089283258.USD","FTXH","IE00B1XK9C88.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","ELIL","LU0289739699.SGD","IE00B7KXQ091.USD","LU0882574139.USD","THNR","LU1720051017.SGD","PPH","LU2552382058.USD","SG9999001176.USD","LU0943347566.SGD","AGNG","LU1023059063.AUD","LU1868836757.USD","LU1989771016.USD","BK4596","LU0689472784.USD","LU0820561909.HKD","LU0238689110.USD","LU0210536198.USD","BK4534","LU2213496289.HKD","LU0672654240.SGD","LU2456880835.USD","LU2237438978.USD","ELIS","CURE","LU0417517546.SGD","LU1291159041.SGD","LU1069344957.HKD","LU2750360997.AUD","LU2756315664.SGD","BK4581","ILDR","LU2237443465.HKD","BK4557","LU2111349929.HKD","LU0787776722.HKD","OZEM","SGXZ31699556.SGD","IE0004445239.USD","IYH","LU0640476718.USD","LU1323610961.USD","LU2063271972.USD","LU0106261372.USD","SGXZ51526630.SGD","IE00BJLML261.HKD","LU2462157665.USD","LU1868837300.USD","LU2023250504.SGD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU2896262040.SGD","LU0820561818.USD","LU1551013425.SGD","LLII","LU2361045086.USD","LU1988902786.USD","LU2023250330.USD","LU0683600562.USD","LU2746668974.SGD","LU0097036916.USD","LU1366192091.USD","LU0006306889.USD","LU2237443549.SGD","SGXZ81514606.USD","LU2471134879.HKD","LU2746668461.USD","IE00BWXC8680.SGD","LU0058720904.USD","LU2471134796.USD","LU0316494557.USD","LLYZ","IE0004445015.USD","IE00BJT1NW94.SGD","LU2168564222.USD","LU2264538146.SGD","LU2361044865.SGD","MEDX","LU0320765059.SGD","LU0432979614.USD","LU2237443622.USD","XLV","LU2491050154.USD","IE00B2B36J28.USD","SG9999017495.SGD","SG9999014906.USD","LU0823434583.USD","LU1093756168.USD","IE0002141913.USD","LU2023251221.USD","IE00BFSS7M15.SGD","BK4585","LU1280957306.USD","TEVA","LU1061106388.HKD","LU2237443382.USD","LU1720051108.HKD","LU2089284900.SGD","VHT","BK4584","LU0122379950.USD","LU0133085943.USD","IE00BK4W5L77.USD","LU1267930730.SGD","LU1623119135.USD","LU2168564149.EUR","LU0158827781.USD","LU1983299246.USD","SG9999018857.SGD","LU1232071149.USD","SG9999015986.USD","LU0354030511.USD","SGXZ57979304.SGD","LU0882574055.USD","LU2236285917.USD","LU0708995401.HKD","LU1917777945.USD","JDOC","LU1868836914.USD","LU2028103732.USD","IXJ","LU2461242641.AUD","LU1145028129.USD","LU0345770308.USD","IE00BN29S564.USD","LU1712237335.SGD","LU0323591593.USD","LU2602419157.SGD","PJP","BK4007","LU1127390331.HKD","LU0786609619.USD","LU2106854487.HKD","LU0266013472.USD","LU1057294990.SGD","LU2168564065.EUR","LU0320765992.SGD","LU1035775433.USD","LLY","LU0225283273.USD","SG9999014880.SGD","SGXZ99366536.SGD","GDOC","LU0256863902.USD","LU2265009873.SGD","LU0353189680.USD","IE00BKDWB100.SGD","LU0964807845.USD","LU1868836591.USD","GB00BDT5M118.USD","IE00BFSS8Q28.SGD","SG9999001176.SGD","SG9999015945.SGD","LU0256863811.USD","LU1629891620.HKD","LU2471134523.USD","LU2361044949.HKD","IE0001KFT4U8.USD","RXL","LU1093756325.SGD","LU2552382132.HKD","LU0109394709.USD","LU0471298777.SGD","LU0823434740.USD","LU2237443895.HKD","LU2271345857.HKD","LU1814569148.SGD","LU2471134952.CNY","MEDI","BK4533","LU0158827948.USD","BK4588","LU2491049909.HKD","LU2168564495.EUR","SG9999015978.USD","IE00BJJMRX11.SGD","IE00B775H168.HKD","BK4599","LU2108987350.USD","SG9999014898.SGD","LU2750360641.GBP","LU1804176565.USD","LU2112291526.USD","SG9999015952.SGD","LU2552382215.SGD","WDNA","IE0005OL40V9.USD","LU2168563687.JPY","LU2211815571.USD","LU0203202063.USD","LU0820562030.AUD","BK4566","LU2324357040.USD","LU0471298694.HKD","LU0385154629.USD","LU1974910355.USD","IE00BJJMRZ35.SGD","CANC","SG9999018865.SGD","LU0061475181.USD","LU2237443978.SGD","LU2360106947.USD","HRTS","IE00B1BXHZ80.USD","LU2491050071.SGD","LU2089984988.USD","LU0096364046.USD","LU0198837287.USD","LU0094547139.USD","LU0353189763.USD","LU2357305700.SGD","SG9999013999.USD","IE00BKPKM429.USD","LU0345770993.USD","LU2417539215.USD","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143570431","title":"异动解读｜梯瓦制药盘中下跌5.17%，报32.86美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143570431","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143570431?lang=zh_cn&edition=full","pubTime":"2026-07-08 23:41","pubTimestamp":1783525298,"startTime":"0","endTime":"0","summary":"7月8日，梯瓦制药盘中下跌5.17%，报32.86美元/股，成交额6018.46万美元。梯瓦制药所在的制药行业中，个股中，礼来跌0.55%，强生跌0.16%，Crinetics Pharmaceuticals跌0.04%，默沙东跌1.71%，辉瑞涨0.93%。梯瓦制药是一家全球性生物制药公司，专注于神经科学和免疫学领域的创新，同时提供复杂的仿制药、生物仿制药和药房品牌。公司下次财报预计于7月29日发布，市场预期EPS为0.37美元。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172668513","title":"梯瓦制药 - 艾考哌姆在儿科患者主要疗效终点上显示出统计学显著获益","url":"https://stock-news.laohu8.com/highlight/detail?id=1172668513","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172668513?lang=zh_cn&edition=full","pubTime":"2026-06-19 04:58","pubTimestamp":1781816323,"startTime":"0","endTime":"0","summary":"梯瓦制药的艾考哌姆在针对儿科患者的关键临床试验中，其首要疗效终点达到了统计学上的显著改善。这一积极结果标志着该药物在目标适应症的研究中取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4596","BK4584","BK4559","BK4585","TEVA","BK4557","LU2324357040.USD","LU1983299246.USD","BK4007","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188750222","title":"梯瓦制药Austedo®与Austedo XR®数据凸显迟发性运动障碍治疗与护理的长期进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1188750222","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188750222?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:01","pubTimestamp":1780920082,"startTime":"0","endTime":"0","summary":"梯瓦制药（Teva Pharmaceutical）公布的数据显示，其Austedo®（氘代丁苯那嗪）片剂与Austedo XR®（氘代丁苯那嗪）缓释片剂，在迟发性运动障碍的治疗与护理方面取得了显著的长期进展。这些数据进一步证实了该药物在管理这一挑战性运动障碍中的持续疗效与价值，为患者提供了更稳定、持久的症状控制方案，有望改善长期治疗结局与生活质量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4557","BK4584","BK4007","BK4566","LU1983299246.USD","TEVA","BK4585","LU2324357040.USD","BK4596","BK4559","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121184893","title":"梯瓦制药拓展欧洲生物类似药版图 推出阿柏西普生物类似药Ahzantive®","url":"https://stock-news.laohu8.com/highlight/detail?id=1121184893","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121184893?lang=zh_cn&edition=full","pubTime":"2026-06-04 20:32","pubTimestamp":1780576370,"startTime":"0","endTime":"0","summary":"梯瓦制药正通过在欧洲市场推出阿柏西普（Aflibercept）生物类似药Ahzantive®，进一步扩大其在该地区的生物类似药产品组合。该药物是眼科重磅药物Eylea®的生物类似药版本。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","LU1983299246.USD","BK4588","BK4559","BK4007","TEVA","BK4585","BK4584","BK4557","BK4566","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118285288","title":"梯瓦研究揭示：仅23%患有情绪障碍与迟发性运动障碍症状的年轻成人获正式TD诊断，尽管影响广泛","url":"https://stock-news.laohu8.com/highlight/detail?id=1118285288","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118285288?lang=zh_cn&edition=full","pubTime":"2026-05-18 20:01","pubTimestamp":1779105679,"startTime":"0","endTime":"0","summary":"一项由梯瓦制药进行的研究发现，在患有情绪障碍并表现出迟发性运动障碍症状的年轻成人群体中，仅有23%的人获得了正式的TD诊断。这一数据凸显出，尽管该疾病的影响广泛存在，但在临床实践中仍存在显著的诊断不足问题。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2324357040.USD","BK4588","TEVA","BK4585","BK4584","BK4557","BK4559","LU1983299246.USD","BK4007","BK4596","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130189018","title":"异动解读 | 梯瓦制药盘中大涨12.02%，第一季度业绩超预期成主要推手","url":"https://stock-news.laohu8.com/highlight/detail?id=1130189018","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130189018?lang=zh_cn&edition=full","pubTime":"2026-04-29 22:31","pubTimestamp":1777473076,"startTime":"0","endTime":"0","summary":"梯瓦制药今日盘中股价大幅上涨12.02%，市场表现强劲。此次股价异动主要得益于公司发布的第一季度业绩报告超出市场预期。报告显示，公司关键创新产品线实现强劲增长，其中AUSTEDO、AJOVY和UZEDY三大核心品牌合计以当地货币计算同比增长高达41%，显著优化了公司的产品组合并推动财务状况改善。具体财务数据显示，梯瓦制药第一季度调整后每股收益为0.53美元，高于市场普遍预期的0.48美元；营收达到40亿美元，也超过了分析师预期的38.1亿美元。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105291761","title":"梯瓦制药高管坦言：2027年调价前渠道库存波动难料","url":"https://stock-news.laohu8.com/highlight/detail?id=1105291761","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105291761?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:48","pubTimestamp":1777466900,"startTime":"0","endTime":"0","summary":"梯瓦制药高管近日表示，针对计划于2027年实施的药品价格调整，目前难以预测是否将引发渠道库存的阶段性收缩。这一表态折射出医药行业在政策过渡期面临的不确定性，企业需在定价策略与供应链动态间寻求平衡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU2324357040.USD","BK4588","BK4585","TEVA","BK4596","BK4557","BK4007","LU1983299246.USD","BK4584","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151082536","title":"梯瓦制药高管称公司运营未受影响，2026年业绩指引无实质性变动——电话会议实录","url":"https://stock-news.laohu8.com/highlight/detail?id=1151082536","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151082536?lang=zh_cn&edition=full","pubTime":"2026-04-29 20:29","pubTimestamp":1777465745,"startTime":"0","endTime":"0","summary":"在最新电话会议中，梯瓦制药（Teva Pharmaceutical）管理层强调，公司当前各项业务活动均保持正常运转状态，未出现任何中断情况。针对市场关注的发展前景，公司明确表示现有运营状况不会对2026年度财务指引产生实质性影响。这一表态进一步强化了投资者对梯瓦制药稳健经营的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","BK4585","BK4559","LU2324357040.USD","TEVA","BK4566","BK4007","BK4557","BK4588","LU1983299246.USD","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164854535","title":"异动解读 | 梯瓦制药盘前大涨7.34%，第一季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1164854535","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164854535?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:34","pubTimestamp":1777462481,"startTime":"0","endTime":"0","summary":"梯瓦制药今日盘前股价大涨7.34%，引起了市场的广泛关注。消息面上，梯瓦制药得益于关键创新产品强劲增长，第一季度业绩超市场预期，这提振了投资者信心，推动了股价的显著上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141249618","title":"得益于关键创新产品强劲增长，梯瓦制药第一季度业绩超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1141249618","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141249618?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:32","pubTimestamp":1777462368,"startTime":"0","endTime":"0","summary":"4月29日，梯瓦制药盘前涨超7%！得益于关键创新产品强劲增长，第一季度业绩超市场预期。此次削减反映了预计的 7 亿美元在研研发费用和与计划收购 Emalex Biosciences 相关的 7500 万美元运营费用。这三个品牌合计以当地货币计算同比增长41%。“我们第一季度的业绩得益于我们关键创新产品的强劲增长，这持续改变着梯瓦的产品组合，并支持其财务状况的改善，”总裁兼首席执行官理查德·弗朗西斯表示。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"得益于关键创新产品强劲增长，梯瓦制药第一季度业绩超预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175650911","title":"财报前瞻｜梯瓦制药本季营收或降4.49%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1175650911","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175650911?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:39","pubTimestamp":1776825546,"startTime":"0","endTime":"0","summary":"梯瓦制药将于2026年04月29日发布最新季度财报。市场一致预期本季度公司营收为38.09亿美元，同比下降4.49%；调整后每股收益为0.47美元，同比上升0.53%；息税前利润为8.90亿美元，同比下降1.77%；目前公开预期未见针对本季度毛利率与净利润或净利率的明确数据。公司上一季度实现营收47.11亿美元，同比增长11.40%；毛利率为56.36%；归属于母公司股东的净利润为4.80亿美元，净利率10.19%；调整后每股收益为0.96美元，同比增长35.21%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜梯瓦制药本季营收或降4.49%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173990339","title":"梯瓦制药与赛诺菲Duvakitug二期B阶段维持治疗数据展现溃疡性结肠炎与克罗恩病具临床意义的持久疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=1173990339","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173990339?lang=zh_cn&edition=full","pubTime":"2026-02-17 19:01","pubTimestamp":1771326072,"startTime":"0","endTime":"0","summary":"梯瓦制药与法国制药巨头赛诺菲联合宣布，其共同研发的药物Duvakitug在二期B阶段临床试验的维持治疗数据中，显示出对溃疡性结肠炎和克罗恩病患者具有临床意义的持久疗效。这一积极结果标志着该疗法在治疗这两种慢性炎症性肠病方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU2324357040.USD","BK4588","BK4585","TEVA","BK4596","BK4557","BK4007","LU1983299246.USD","BK4584","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136364632","title":"梯瓦制药2026年收入指引不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1136364632","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136364632?lang=zh_cn&edition=full","pubTime":"2026-01-28 22:17","pubTimestamp":1769609869,"startTime":"0","endTime":"0","summary":"$梯瓦制药$ 周三盘前股价下跌，此前其 2026 年收入预测低于华尔街预期。梯瓦预计调整后每股收益将在 2.57 至 2.77 美元 之间。梯瓦的美国存托凭证盘前下跌 4.46%。这家总部位于以色列特拉维夫的公司正努力将业务从核心仿制药业务多元化。梯瓦第四季度的销售额和利润均超过分析师预期。包括 Austedo 和 Ajovy 在内的关键品牌药物季度收入首次超过 10 亿美元。公司表示，在10月至12月季度，经剔除一次性项目后，每股摊薄收益为0.96美元，高于去年同期的0.71美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/94df2a61e08c14e61fc34d863dd23506","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/94df2a61e08c14e61fc34d863dd23506"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113220944","title":"财报前瞻 ｜梯瓦制药本季度营收预计增4.95%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1113220944","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113220944?lang=zh_cn&edition=full","pubTime":"2026-01-21 10:20","pubTimestamp":1768962021,"startTime":"0","endTime":"0","summary":"梯瓦制药将于2026年01月28日发布最新季度财报，市场聚焦收入和EPS同比表现及核心产品线的持续推进。市场一致预期显示，本季度梯瓦制药总收入预计为43.35亿美元，同比增长4.95%；毛利率、净利率与调整后每股收益的本季度预测未在公开预期中明确披露，EPS一致预期为0.64美元，同比下降8.70%，EBIT预计为10.84亿美元，同比下降11.05%。公司在上一季度财报沟通中并未给出对本季度毛利率与净利率的量化指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜梯瓦制药本季度营收预计增4.95%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518274873","title":"梯瓦制药盘中异动 急速下跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518274873","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518274873?lang=zh_cn&edition=full","pubTime":"2025-03-10 23:09","pubTimestamp":1741619345,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日23时09分，梯瓦制药股票出现波动，股价急速跳水5.01%。梯瓦制药股票所在的制药行业中，整体跌幅为1.97%。梯瓦制药公司简介：梯瓦制药工业有限公司总部位于以色列，是世界领先的仿制药制造商。梯瓦一半的销售额来自北美，在美国仿制药处方总数中所占的比例很高，为个位数。梯瓦还销售活性药物成分，提供合同制造服务，并拥有美国仿制药和特种药分销商Anda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310230905abf32054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310230905abf32054&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4557","TEVA","BK4584","BK4566","BK4596","BK4588","BK4559","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517216414","title":"B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517216414","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517216414?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:46","pubTimestamp":1741275975,"startTime":"0","endTime":"0","summary":"B of A Securities：维持Teva Pharmaceutical Indus(TEVA.US)评级，由买入调整至买入评级, 目标价由23.00美元调整至20.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06234648576704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TEVA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514803042","title":"赛诺菲(SNY.US)与梯瓦(TEVA.US)共同开发的duvakitug预计在下半年启动3期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803042","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514803042?lang=zh_cn&edition=full","pubTime":"2025-02-25 14:33","pubTimestamp":1740465193,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，赛诺菲与梯瓦日前公布了其共同开发的在研单抗duvakitug在2b期临床试验RELIEVE UCCD中获得的详细结果。新闻稿表示，这一结果展现了duvakitug成为“best-in-class”疗法的潜力。两家公司预计在今年下半年启动3期临床试验。2b期临床试验数据显示，接受duvakitug治疗的UC患者中，36%的低剂量组和48%高剂量组患者实现临床缓解，此数值在安慰剂组仅为20%。靶向TL1A有望缓解IBD患者的过度免疫反应。赛诺菲与梯瓦在2023年达成合作，共同开发并商业化duvakitug，用于治疗UC和CD。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1253916.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1583","03347","BK4007","BK4559","BK4557","BK4584","TEVA","SNY","BK4566","BK4588","BK1576","BK4596","IE00BFXG1179.USD","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512481529","title":"梯瓦制药盘中异动 股价大涨5.01%报17.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512481529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512481529?lang=zh_cn&edition=full","pubTime":"2025-02-20 00:04","pubTimestamp":1739981061,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日00时04分，梯瓦制药股票出现波动，股价大幅拉升5.01%。截至发稿，该股报17.40美元/股，成交量390.546万股，换手率0.34%，振幅4.53%。最近的财报数据显示，该股实现营业收入165.10亿美元，净利润-16.39亿美元，每股收益-1.45美元，毛利80.29亿美元，市盈率-11.97倍。梯瓦制药股票所在的制药行业中，整体涨幅为1.34%。梯瓦还销售活性药物成分，提供合同制造服务，并拥有美国仿制药和特种药分销商Anda。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000421abd511a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220000421abd511a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4007","BK4559","BK4584","BK4557","TEVA","BK4566","BK4588","BK4596"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.tevapharm.com","stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0163},{"period":"3month","weight":-0.0114},{"period":"6month","weight":0.0085},{"period":"1year","weight":0.9638},{"period":"ytd","weight":0.0263}],"compareEarnings":[{"period":"1week","weight":-0.0154},{"period":"1month","weight":0.0031},{"period":"3month","weight":0.0467},{"period":"6month","weight":0.0746},{"period":"1year","weight":0.1835},{"period":"ytd","weight":0.09}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Teva Pharmaceutical Industries Limited于1944年2月13日在以色列注册成立。该公司是一家全球性生物制药公司，拥有重要的仿制药业务，在全球约57个市场开展业务。它专注于神经科学和免疫学领域的创新，同时提供复杂的仿制药、生物仿制药和药房品牌，以满足患者的需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.063449},{"month":2,"riseRate":0.357143,"avgChangeRate":-0.01732},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.019164},{"month":4,"riseRate":0.357143,"avgChangeRate":0.006451},{"month":5,"riseRate":0.5,"avgChangeRate":-0.00523},{"month":6,"riseRate":0.466667,"avgChangeRate":0.009278},{"month":7,"riseRate":0.533333,"avgChangeRate":0.021893},{"month":8,"riseRate":0.214286,"avgChangeRate":-0.047364},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.0119},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.019229},{"month":11,"riseRate":0.642857,"avgChangeRate":0.061945},{"month":12,"riseRate":0.571429,"avgChangeRate":0.030034}],"exchange":"NYSE","name":"梯瓦制药","nameEN":"Teva Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"梯瓦制药,TEVA,梯瓦制药股票,梯瓦制药股票老虎,梯瓦制药股票老虎国际,梯瓦制药行情,梯瓦制药股票行情,梯瓦制药股价,梯瓦制药股市,梯瓦制药股票价格,梯瓦制药股票交易,梯瓦制药股票购买,梯瓦制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"梯瓦制药(TEVA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供梯瓦制药(TEVA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}